Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias
- 28 August 2015
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 48 (1) , 105-114
Abstract
Background: Overexpression of the mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10, which is also known as the intracellular amyloid-β peptide (Aβ) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer’s disease (AD). It appears that 17β-HSD10 may play a role in the pathogenesis of AD. Objective: We investigated the possibility that levels of 17β-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. Methods: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of Aβ 1 - 42 , tau, and phospho-tau. Results: We found significantly higher levels of 17β-HSD10 in people with MCI due to AD (to 109.9% ), with AD (to 120.0% ), or with other types of dementia (to 110.9% ) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0% , and the specificity was 73.3% (compared to controls) or 52.5–59.1% (compared to other types of dementia). Results of multiple linear regression and of correlation analysis revealed AD-mediated changes in links between 17β-HSD10 and Mini Mental State Examination score. Conclusion: It seems that changes in 17β-HSD10 start many years before symptom onset, analogous to those in Aβ 1 - 42 , tau, or phospho-tau and that the levels are a relatively highly sensitive but unfortunately less specific biomarker of AD. A role of 17β-HSD10 overexpression in AD is discussed.Keywords
This publication has 38 references indexed in Scilit:
- Overexpression of 17β-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell deathBMC Cancer, 2015
- Mutation or knock-down of 17β-hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcriptsHuman Molecular Genetics, 2014
- Role of Mitochondrial Amyloid-β in Alzheimer's DiseaseJournal of Alzheimer’s Disease, 2010
- A non‐enzymatic function of 17β‐hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survivalEMBO Molecular Medicine, 2010
- Mental retardation linked to mutations in the HSD17B10 gene interfering with neurosteroid and isoleucine metabolismProceedings of the National Academy of Sciences, 2009
- Submicroscopic Duplications of the Hydroxysteroid Dehydrogenase HSD17B10 and the E3 Ubiquitin Ligase HUWE1 Are Associated with Mental RetardationThe American Journal of Human Genetics, 2008
- Mitochondrial dysfunction and Alzheimer's disease: role of amyloid‐β peptide alcohol dehydrogenase (ABAD)International Journal of Experimental Pathology, 2005
- L‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's diseaseAnnals of Neurology, 2004
- scully, an Essential Gene of Drosophila, is Homologous to Mammalian Mitochondrial Type II l-3-hydroxyacyl-CoA Dehydrogenase/Amyloid-β Peptide-binding ProteinJournal of Cell Biology, 1998
- An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's diseaseNature, 1997